Mutants of lymphotoxin-α with augmented cytotoxic activity via TNFR1 for use in cancer therapy

Cytokine

Volumn 61, Issue 2, 2013, Pages 578-584

  Morishige, Tomohiro ^a   Yoshioka, Yasuo ^a   Narimatsu, Shogo ^a   Ikemizu, Shinji ^b   Tsunoda, Shin ichi ^a,c   Tsutsumi, Yasuo ^a,c   Mukai, Yohei ^a   Okada, Naoki ^a   Nakagawa, Shinsaku ^a  

^a OSAKA UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

Affinity; Apoptosis; Bioactivity; Cytokine; Cytotoxicity

Indexed keywords

ALANINE; AMINO ACID; ASPARAGINE; ASPARTIC ACID; CASPASE 3; CASPASE 7; CASPASE 8; GLYCINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUCINE; LYMPHOTOXIN; LYSINE; SERINE; THREONINE; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VALINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; DISSOCIATION; DRUG CYTOTOXICITY; ENZYME ACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; MOLECULAR CLONING; PHAGE DISPLAY; PRIORITY JOURNAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION; WILD TYPE;

AMINO ACID SEQUENCE; CASPASES; CELL DEATH; CELL LINE, TUMOR; ELECTRON SPIN RESONANCE SPECTROSCOPY; ENZYME ACTIVATION; HUMANS; ISOELECTRIC POINT; KINETICS; LYMPHOTOXIN-ALPHA; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; NEOPLASMS; NF-KAPPA B; PROTEIN BINDING; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I;

EID: 84873112493     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.11.005     Document Type: Article

References (26)

1. Neumann B., Luz A., Pfeffer K., Holzmann B. Defective Peyer's patch organogenesis in mice lacking the 55-kD receptor for tumor necrosis factor. J Exp Med 1996, 184:259-264.
2. Kratz A., Campos-Neto A., Hanson M.S., Ruddle N.H. Chronic inflammation caused by lymphotoxin is lymphoid neogenesis. J Exp Med 1996, 183:1461-1472.
3. Koni P.A., Sacca R., Lawton P., Browning J.L., Ruddle N.H., Flavell R.A. Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice. Immunity 1997, 6:491-500.
4. Schrama D., thor Straten P., Fischer W.H., McLellan A.D., Brocker E.B., Reisfeld R.A., et al. Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity 2001, 14:111-121.
5. Schrama D., Voigt H., Eggert A.O., Xiang R., Zhou H., Schumacher T.N., et al. Immunological tumor destruction in a murine melanoma model by targeted LTalpha independent of secondary lymphoid tissue. Cancer Immunol Immunother 2008, 57:85-95.
6. Ryan S.M., Mantovani G., Wang X., Haddleton D.M., Brayden D.J. Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opin Drug Deliv 2008, 5:371-383.
7. Yamamoto Y., Tsutsumi Y., Yoshioka Y., Nishibata T., Kobayashi K., Okamoto T., et al. Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat Biotechnol 2003, 21:546-552.
8. Shibata H., Yoshioka Y., Ikemizu S., Kobayashi K., Yamamoto Y., Mukai Y., et al. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window. Clin Cancer Res 2004, 10:8293-8300.
9. Narimatsu S., Yoshioka Y., Watanabe H., Masano T., Morishige T., Yao X., et al. Lysine-deficient lymphotoxin-alpha mutant for site-specific PEGylation. Cytokine 2011, 56:489-493.
10. Everaerdt B., Brouckaert P., Shaw A., Fiers W. Four different interleukin-1 species sensitize to the lethal action of tumour necrosis factor. Biochem Biophys Res Commun 1989, 163:378-385.
11. Brouckaert P., Libert C., Everaerdt B., Fiers W. Selective species specificity of tumor necrosis factor for toxicity in the mouse. Lymphokine Cytokine Res 1992, 11:193-196.
12. Yoshioka Y., Watanabe H., Morishige T., Yao X., Ikemizu S., Nagao C., et al. Creation of lysine-deficient mutant lymphotoxin-alpha with receptor selectivity by using a phage display system. Biomaterials 2010, 31:1935-1943.
13. Browning J.L., Miatkowski K., Sizing I., Griffiths D., Zafari M., Benjamin C.D., et al. Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines. J Exp Med 1996, 183:867-878.
14. Abe Y., Yoshikawa T., Kamada H., Shibata H., Nomura T., Minowa K., et al. Simple and highly sensitive assay system for TNFR2-mediated soluble- and transmembrane-TNF activity. J Immunol Methods 2008, 335:71-78.
15. Nicholls A., Sharp K.A., Honig B. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins 1991, 11:281-296.
16. Mizuguchi K., Deane C.M., Blundell T.L., Johnson M.S., Overington J.P. JOY: protein sequence-structure representation and analysis. Bioinformatics 1998, 14:617-623.
17. Sheikh M.S., Huang Y. Death receptor activation complexes: it takes two to activate TNF receptor 1. Cell Cycle 2003, 2:550-552.
18. Chen G., Goeddel D.V. TNF-R1 signaling: a beautiful pathway. Science 2002, 296:1634-1635.
19. Magne N., Toillon R.A., Bottero V., Didelot C., Houtte P.V., Gerard J.P., et al. NF-kappaB modulation and ionizing radiation: mechanisms and future directions for cancer treatment. Cancer Lett 2006, 231:158-168.
20. Hlavacek W.S., Redondo A., Metzger H., Wofsy C., Goldstein B. Kinetic proofreading models for cell signaling predict ways to escape kinetic proofreading. Proc Nat Acad Sci USA 2001, 98:7295-7300.
21. Liu Z.J., Haleem-Smith H., Chen H., Metzger H. Unexpected signals in a system subject to kinetic proofreading. Proc Nat Acad Sci USA 2001, 98:7289-7294.
22. Krippner-Heidenreich A., Tubing F., Bryde S., Willi S., Zimmermann G., Scheurich P. Control of receptor-induced signaling complex formation by the kinetics of ligand/receptor interaction. J Biol Chem 2002, 277:44155-44163.
23. Torigoe C., Faeder J.R., Oliver J.M., Goldstein B. Kinetic proofreading of ligand-FcepsilonRI interactions may persist beyond LAT phosphorylation. J Immunol 2007, 178:3530-3535.
24. Kim J.Y., Lee J.Y., Kim D.G., Koo G.B., Yu J.W., Kim Y.S. TRADD is critical for resistance to TRAIL-induced cell death through NF-kappaB activation. FEBS Lett 2011, 585:2144-2150.
25. Arch R.H., Gedrich R.W., Thompson C.B. Tumor necrosis factor receptor-associated factors (TRAFs) - a family of adapter proteins that regulates life and death. Genes Dev 1998, 12:2821-2830.
26. Deveraux Q.L., Reed J.C. IAP family proteins-suppressors of apoptosis. Genes Dev 1999, 13:239-252.